The profound influence of treatment on the subclonal structure of breast cancer has also been delineated in human epidermal growth factor receptor 2 (HER2)-positive tumours using a method that visualises driver mutation heterogeneity in different tumour subpopulations [7]. This evidence concerns the gene ERBB2 and breast cancer.